Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa)

S. Segal, I. Y. Shemesh, R. Blumenthal, B. Yoffe, N. Laufer, Y. Ezra, I. Levy, M. Mazor, U. Martinowitz

Research output: Contribution to journalArticlepeer-review

69 Scopus citations


Recombinant activated factor VII (rFVIIa, NovoSeven®) was used in three patients with massive obstetric hemorrhage due to placenta previa accreta, rupture of the uterus and pre-eclampsia with HELLP. Administration of the drug markedly decreased the bleeding and enabled control of the hemorrhage. rFVIIa seems to be an adjunctive hemostatic measure for the treatment of severe obstetric hemorrhage.

Original languageEnglish
Pages (from-to)266-267
Number of pages2
JournalArchives of Gynecology and Obstetrics
Issue number4
StatePublished - 1 Oct 2003


  • Factor VIIa
  • Hemorrhage
  • Postpartum hemorrhage

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa)'. Together they form a unique fingerprint.

Cite this